Evaluation of the effect of L-Carnitine on patients with moderate to severe condition of Covid-19 ?admitted to critical care unit

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141209020258N165

Enrollment

Registered

2021-09-10

Start date

2021-09-23

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

With Quid-19 with moderate disease severity. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: In addition to routine treatment, patients will receive 1 gram of L-carnitine supplement per day (Karen 1000 mg L-carnitine tablets) for 7 days. Intervention 2: Con

Eligibility

Sex/Gender

All

Age

28 Years to 75 Years

Inclusion criteria

Inclusion criteria: Suffering Covid-19 without intubation Apache less than 25 28 to 75 years Absence of acute asthma Absence of acute pulmonary hemorrhage Absence of lung tumor Absence of untreated pneumothorax Do not take anticoagulants (coumadin group such as warfarin) No history of kidney or liver disease No diabetes (because of the risk of hypoglycemia) No history of seizures

Exclusion criteria

Exclusion criteria: Death Patient dissatisfaction with attending the study for any reason

Design outcomes

Primary

Measure	Time frame
Intravenous blood gas samples. Timepoint: Daily. Method of measurement: Intravenous blood samples.;Disease severity. Timepoint: Daily. Method of measurement: Checklist Apache II.;Length of hospital stay. Timepoint: End of study. Method of measurement: Patient file.;Mortality. Timepoint: End of study. Method of measurement: Patient file.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hesamedin Modir

Arak University of Medical Sciences

modir.he@gmail.com+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026